Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026
Capstone Holding Corp. Common Stock · Now $0.34
-48% since the alert
$0.66 → $0.34
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS